OncoMatch/Clinical Trials/NCT06315010
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Is NCT06315010 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Repotrectinib for nsclc.
Treatment: Repotrectinib — REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ROS1 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: ros1 tyrosine kinase inhibitor
Lab requirements
Blood counts
WBC > 3.0 x 10^9/L, ANC ≥ 1.5 x 10^9/L, platelets ≥ 100.0 x 10^9/L, hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L); no transfusion or G-CSF support within 28 days
Kidney function
Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 40 mL/min/1.73 m2 (Cockcroft-Gault)
Liver function
Total bilirubin ≤ 1.5x ULN (≤ 3x ULN with liver metastases or Gilbert's disease); ALP ≤ 2.5x ULN; AST/ALT ≤ 3x ULN (≤ 5x ULN with liver metastases); INR < 1.5
Cardiac function
LVEF ≥ 50% by ECHO or MUGA; mean resting QTc ≤ 470 msec; no clinically important ECG abnormalities; no factors increasing risk of QTc prolongation or arrhythmia; no significant cardiovascular disease (see exclusion 6)
Patient has adequate bone marrow, liver, and renal function: ... LVEF ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. ... See exclusion criteria for cardiac details.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06315010 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior ros1 tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require ROS1?
Yes, ROS1 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify